{"filing":{"accession_number":"0001829126-26-009977","cik":"0001979414","ticker":"NTHI","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-08","primary_document":"neonctechnologies_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1979414/000182912626009977/neonctechnologies_8k.htm"},"events":[{"id":32590,"run_id":29950,"accession_number":"0001829126-26-009977","anchor_item_number":"1.01","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"NeOnc Technologies entered into securities purchase agreements on September 8, 2026, for a registered direct offering of approximately 3.6 million shares of common stock (or pre-funded warrants) and accompanying warrants, raising approximately $15 million in gross proceeds. The offering was priced at-the-market under Nasdaq rules and includes pre-funded warrants exercisable at $0.0001 and regular warrants exercisable at $4.20, representing material dilution to existing shareholders.","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35796,"accession_number":"0001829126-26-009977","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NeOnc entered into securities purchase agreements on September 8, 2026, for a registered direct offering of approximately 3.6 million shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants, raising approximately $15 million in gross proceeds. This is a registered equity issuance with significant dilution to existing shareholders, structured as a registered direct offering under the company's effective Form S-3 shelf registration statement. The offering includes pre-funded warrants exercisable at $0.0001 and regular warrants exercisable at $4.20, both of which are dilutive instruments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T14:28:40.614525+00:00","company_name":"","ticker":null,"filing_date":""},{"id":35797,"accession_number":"0001829126-26-009977","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"NeOnc announced pricing of a $15 million registered direct offering of 3,571,430 shares of common stock (or pre-funded warrants) plus accompanying warrants at $4.20 per share. This is a dilutive equity issuance to institutional investors under a registered shelf offering, representing a material capital raise for a clinical-stage biopharmaceutical company. The press release explicitly states the offering is \"priced at-the-market under Nasdaq rules\" and involves both new and existing institutional investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T14:28:40.614525+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35796,"accession_number":"0001829126-26-009977","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"NeOnc entered into securities purchase agreements on September 8, 2026, for a registered direct offering of approximately 3.6 million shares of common stock (or pre-funded warrants in lieu thereof) and accompanying warrants, raising approximately $15 million in gross proceeds. This is a registered equity issuance with significant dilution to existing shareholders, structured as a registered direct offering under the company's effective Form S-3 shelf registration statement. The offering includes pre-funded warrants exercisable at $0.0001 and regular warrants exercisable at $4.20, both of which are dilutive instruments.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T14:28:40.614525+00:00","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-09-10"},{"id":35797,"accession_number":"0001829126-26-009977","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"dilutive_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"NeOnc announced pricing of a $15 million registered direct offering of 3,571,430 shares of common stock (or pre-funded warrants) plus accompanying warrants at $4.20 per share. This is a dilutive equity issuance to institutional investors under a registered shelf offering, representing a material capital raise for a clinical-stage biopharmaceutical company. The press release explicitly states the offering is \"priced at-the-market under Nasdaq rules\" and involves both new and existing institutional investors.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T14:28:40.614525+00:00","company_name":"NEONC TECHNOLOGIES HOLDINGS, INC.","ticker":"NTHI","filing_date":"2026-09-10"}]}